TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10771863
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of prolonged latency and prolonged interval
Study: 28571996
Drug: Etanercept (TNF-alpha
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept (TNF-alpha inhibitor)
Study: 16959828
Drug: GFR <40
Approvals — FDA: no, EMA: no, PMDA: no
Description: GFR <40 ml/min
Study: 15488354
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg micronised 17 beta‐oestradiol/5 mg dydrogesterone (E/D)
Study: 15488354
Drug: 0.625 mg
Normalized name: estrone 0.625 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625 mg conjugated equine oestrogens/5 mg medroxyprogesterone acetate (CEE/MPA)
Study: 7826792
Drug: Extradural sufentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extradural sufentanil (initial bolus of 50 micrograms followed by 10 micrograms, self-administered using PCA, mean 275 micrograms)
Study: 7826792
Drug: Extradural sufentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extradural sufentanil (initial bolus of 50 micrograms followed by 10 micrograms, administered by a nurse on request, mean 144 micrograms)
Study: 7826792
Drug: i.m. morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.m. morphine (mean 52 mg, range 30‐80 mg, administered on request)
Study: 28754119
Drug: YY-312 (2400
Approvals — FDA: no, EMA: no, PMDA: no
Description: YY-312 (2400 mg daily, containing 1800 mg of active herbal extract and 600 mg of cyclodextrin)
Study: 26618455
Drug: VYC‐20L (hyaluronic
Approvals — FDA: no, EMA: no, PMDA: no
Description: VYC‐20L (hyaluronic acid gel)
Study: 20863604
Drug: Natural childbirth
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natural childbirth preparation with psychoprophylaxis
Study: 19485825
Drug: Acetaminophen 500
Normalized name: acetaminophen 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 500 mg with caffeine 30 mg
Study: 14686080
Drug: Comprehensive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive treatment package targeting headache symptoms and associated posttraumatic stress symptoms
Study: 14686080
Drug: Comprehensive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive treatment package
Study: 12549975
Drug: Intravenous vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous vitamin C (2 g)
Study: 12549975
Drug: Oral vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin C (4 g/day for 4 weeks)
Study: 11024416
Drug: Topical beta-blockers
Normalized name: Beta-HC Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical beta-blockers
Study: 11024416
Drug: Close observation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Close observation (no topical medication)
Study: 6362832
Drug: Immunotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy with nonviable Mycobacterium smegmatis, given monthly by subcutaneous injection in four sites.
Study: 6171572
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (not specified treatment).
Study: 3543092
Drug: Diltiazem (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (90 to 360 mg)
Study: 3543092
Drug: Nifedipine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (30 to 120 mg)
Study: 3543092
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of diltiazem and nifedipine
Study: 31811562
Drug: Apheresis therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apheresis therapy (twice per month for 12 months)
Study: 31811562
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no apheresis treatment)
Study: 23249916
Drug: Extended infant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended infant nevirapine (NVP) administration
Study: 23249916
Drug: Maternal antiretroviral
Normalized name: undecylenate
DrugBank: Undecylenic acid (DB11117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maternal antiretroviral treatment regimen (including NVP or efavirenz)
Study: 23249916
Drug: No maternal
Approvals — FDA: no, EMA: no, PMDA: no
Description: No maternal antiretroviral treatment
Study: 19564304
Drug: Moderate-dose methylphenidate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate-dose methylphenidate (0.6 mg/kg; 20 mg twice daily maximum)
Study: 19564304
Drug: Low-dose methylphenidate
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose methylphenidate (0.3 mg/kg; 10 mg twice daily maximum)
Study: 17083767
Drug: Initial combination
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial combination therapy with methotrexate, sulphasalazine, and tapered high dose of prednisone
Study: 17083767
Drug: Initial combination
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial combination therapy with methotrexate and infliximab
Study: 17083767
Drug: Step up
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Step up to combination therapy starting with methotrexate
Study: 9202949
Drug: 6% glucose-electrolyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6% glucose-electrolyte solution (GS)
Study: 9202949
Drug: 6% maltodextrin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6% maltodextrin solution
Study: 9202949
Drug: 6% maltodextrin-electrolyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6% maltodextrin-electrolyte solution
Study: 3440105
Drug: Omeprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (20 mg) given as enteric-coated granules
Study: 3440105
Drug: Antacid (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antacid (10 ml, buffering capacity 56.6 mmol 10 ml‐1)
Study: 21920001
Drug: Mebeverine 135
Normalized name: mebeverine 135 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mebeverine 135 mg three times daily
Study: 18665032
Drug: Mupirocin ointment
Normalized name: Mupirocin Ointment
DrugBank: Mupirocin (DB00410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mupirocin ointment therapy
Study: 16715358
Drug: Fixed dose
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed dose of pertuzumab (420 or 1050 mg)
Study: 16715358
Drug: Weight-based dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight-based dosing (0.5-15 mg/kg)
Study: 12525510
Drug: BSA-based dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: BSA-based dosing
Study: 12559533
Drug: Clopidogrel 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 1 x 300 mg as a loading dose, and 1 x 75 mg per day thereafter
Study: 9424002
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose radiation therapy (60 Gy continuously) and daily cisplatin (6 mg/sqm/day)
Study: 8276050
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ramipril and propranolol
Study: 9629648
Drug: Sequential test
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential test
Study: 30611113
Drug: The Pink
Normalized name: THE-630
DrugBank: THE-630 (DB16750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The Pink Kit Method for Birthing Better® (CKT, 2001), a multi-media, skills-based and self-directed childbirth preparation programme.
Study: 24907502
Drug: Medium-dose oral
Normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium-dose oral budesonide suspension (OBS)
Study: 24907502
Drug: High-dose oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose oral budesonide suspension (OBS)
Study: 24907502
Drug: Low-dose oral
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose oral budesonide suspension (OBS)
Study: 16990383
Drug: Intracoronary injection
Normalized name: HELIUM 992 mL in 1 L INTRACORONARY GAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary injection of autologous mononuclear bone marrow cells (BMC)
Study: 17130431
Drug: Orally administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally administered CC chemokine receptor 1 (CCR1) antagonist
Study: 10912264
Drug: Treatment of
Normalized name: DRUGS FOR TREATMENT OF LEPRA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of nasal allergy for a period of at least four months
Study: 2883406
Drug: 0.6 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 g/kg intravenous immunoglobulin
Study: 2883406
Drug: 0.2 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 g/kg intravenous immunoglobulin
Study: 24215475
Drug: Topical 5-aminolevulinic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 5-aminolevulinic acid (ALA) photodynamic therapy (PDT) with light dose of 70 J/cm2
Study: 24215475
Drug: Topical 5-aminolevulinic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 5-aminolevulinic acid (ALA) photodynamic therapy (PDT) with light dose of 100 J/cm2
Study: 12115321
Drug: Perilymphatic recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perilymphatic recombinant IL‐2 (rIL‐2) administered at 5000 units daily for 10 days before surgery and monthly for 1 year after surgery.
Study: 7579136
Drug: 0.15 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15 IU insulin kg‐1
Study: 1537779
Drug: Nortriptyline (active
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nortriptyline (active treatment)
Study: 22613136
Drug: abciximab infusion
Normalized name: Abciximab
DrugBank: Abciximab (DB00054)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: abciximab infusion
Study: 24621976
Drug: placebo infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo infusion
Study: 17697305
Drug: Dexmedetomidine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (1 microg/kg bolus and infusion at a rate of 0.7 microg/kg/h)
Study: 11642510
Drug: Serum transferrin
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum transferrin receptor (s‐TfR) levels in RA patients
Study: 11367653
Drug: Feiyan Chuansou
Approvals — FDA: no, EMA: no, PMDA: no
Description: Feiyan Chuansou Oral Liquid (FCOL)
Study: 7882780
Drug: St. Thomas
Normalized name: St. Thomas lidpod
Approvals — FDA: no, EMA: no, PMDA: no
Description: St. Thomas group (CC)
Study: 2975567
Drug: Three times
Normalized name: WELLBUTRIN 100 MG Oral Tablet, Three Times Daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three times daily pen regimen with human ultralente at night
Study: 2975553
Drug: Twice daily
Normalized name: CAPSULE, TWICE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily insulin regimen
Study: 25952532
Drug: Basal-prandial insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Basal-prandial insulin (stepwise addition of insulin glulisine)
Study: 25952532
Drug: Premixed insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Premixed insulin (insulin aspart/insulin aspart protamine 30/70 starting with 6IU twice daily)
Study: 23314694
Drug: 2.0 μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 μg/kg fentanyl
Study: 23314694
Drug: 4.0 μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.0 μg/kg fentanyl
Study: 20498403
Drug: Bevacizumab 15
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab 15 mg/kg plus docetaxel 100 mg/m(2)
Study: 20498403
Drug: Bevacizumab 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab 7.5 mg/kg plus docetaxel 100 mg/m(2)
Study: 20498403
Drug: Docetaxel 100
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 100 mg/m(2) plus placebo
Study: 20150572
Drug: Bevacizumab 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab 7.5 mg/kg
Study: 19098989
Drug: Monthly artesunate
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly artesunate plus amodiaquine (AS+AQ)
Study: 15908136
Drug: Self-reported substance
Normalized name: black imported fire ant allergenic extract
DrugBank: Solenopsis richteri (DB11026)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-reported substance abuse treatment contact after enrollment
Study: 10720292
Drug: Modafinil (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modafinil (both doses)
Study: 1465034
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg 17 beta‐oestradiol and different doses of progesterone (50, 100 or 200 mg)
Study: 29907581
Drug: Empagliflozin 25
Normalized name: empagliflozin 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin 25 mg (EMPA-REG H2H-SU trial)
Study: 26465829
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (233 mg zinc gluconate containing 30 mg zinc) for 6 weeks
Study: 17543812
Drug: Levobupivacaine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levobupivacaine infusion (50 hours)
Study: 17543812
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusion (50 hours)
Study: 11982742
Drug: Medroxyprogesterone acetate
Normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medroxyprogesterone acetate (MPA) 60 mg day -1
Study: 10441040
Drug: 25 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg/kg (b.w.) of nicotinamide (NA)
Study: 10441040
Drug: 50 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg/kg (b.w.) of nicotinamide (NA)
Study: 10441040
Drug: Both doses
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both doses of nicotinamide (25 mg/kg and 50 mg/kg)
Study: 2077983
Drug: Midazolam 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.4 mg/kg
Study: 2077983
Drug: Diazepam 0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam 0.75 mg/kg
Study: 348536
Drug: Metopimazine 30
Normalized name: metopimazine
DrugBank: Metopimazine (DB13591)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metopimazine 30 mg/day or 15 mg/day
Study: 348536
Drug: Metopimazine 45
Normalized name: metopimazine
DrugBank: Metopimazine (DB13591)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metopimazine 45 mg/day
Study: 19236356
Drug: Buprenorphine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine treatment for heroin dependence
Study: 10742705
Drug: Exercise programme
Normalized name: Immunoglobulin G4, anti-programmed cell death protein 1 (PDCD1) (humanized clone ABT1 gamma4-chain), disulfide with humanized clone ABT1 kappa-chain, dimer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise programme (once weekly sessions for 12 weeks)
Study: 9475306
Drug: Glucose oral
Normalized name: glucose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose oral rehydration solution (ORS)
Study: 30858203
Drug: Daptomycin plus
Normalized name: Daptomycin
DrugBank: Daptomycin (DB00080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daptomycin plus Ceftaroline (DAPCPT) - 6 to 8 mg/kg of body weight per day of DAP and 600 mg intravenous CPT every 8 hours (n 17)
Study: 30858203
Drug: Standard monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard monotherapy - Vancomycin (VAN; dosed to achieve serum trough concentrations of 15 to 20 mg/liter; n 21) or 6 to 8 mg/kg/day DAP (n 2) (n 23 total)
Study: 30858203
Drug: Daptomycin plus
Normalized name: Daptomycin
DrugBank: Daptomycin (DB00080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daptomycin plus Ceftaroline (DAPCPT) - among patients with IL-10 concentration of 5 pg/ml (n 14)
Study: 30858203
Drug: Standard monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard monotherapy - among patients with IL-10 concentration of 5 pg/ml (n 19)
Study: 29993140
Drug: Standardised oral
Normalized name: standardized senna concentrate Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardised oral health examination by registered dental hygienists
Study: 22686185
Drug: 18 months
Normalized name: treprostinil
DrugBank: Treprostinil (DB00374)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 18 months of weekly psychoanalytic psychotherapy, manualised and fidelity‐assessed using the Psychotherapy Process Q‐Sort.
Study: 22686185
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual, managed by the referring practitioner.
Study: 20830664
Drug: Desvenlafaxine (50,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desvenlafaxine (50, 100, 200, or 400 mg/d)
Study: 18555464
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose chemotherapy (HDCT) with melphalan 200 mg/m² and autologous peripheral stem cell transplantation (APSCT)
Study: 18555464
Drug: Thalidomide maintenance
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Thalidomide maintenance therapy at 100 mg/day
Study: 7586952
Drug: Phentolamine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phentolamine (10 mg, intravenous)
Study: 7586952
Drug: Prazosin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin (5 mg, orally)
Study: 7586952
Drug: Nicardipine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine (2 micrograms/kg/min, continuous intravenous infusion)
Study: 2254715
Drug: Multiple injections
Normalized name: sodium acetate
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multiple injections (MI) with human isophane insulin
Study: 2254715
Drug: Multiple injections
Normalized name: sodium acetate
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multiple injections (MI) with human ultralente insulin
Study: 2254715
Drug: Intensified therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensified therapy (CSII and MI)
Study: 2254715
Drug: Intensified insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensified insulin therapy (CSII and MI)
Study: 7029388
Drug: Topical 1%
Normalized name: fluoride topical 1% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 1% aqueous indomethacin
Study: 31646414
Drug: High-dose spinal
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose spinal analgesia (levobupivacaine 7.5 mg plus sufentanil 2.5 μg)
Study: 31646414
Drug: Low-dose spinal
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose spinal analgesia (levobupivacaine 3.75 mg plus sufentanil 2.5 μg)
Study: 31646414
Drug: High-dose spinal
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose spinal analgesia during laparoscopy
Study: 31646414
Drug: Low-dose spinal
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose spinal analgesia during laparoscopy
Study: 28295463
Drug: RG-101 2
Normalized name: DNA, D((2'-O-(2-METHOXYETHYL))M5RC-SP-(2'-O-(2-METHOXYETHYL))RA-(2'-O-(2-METHOXYETHYL))RG-SP-(2'-O-(2-METHOXYETHYL))RG-(2'-O-(2-METHOXYETHYL))RA-SP-T-SP-A-SP-M5C-SP-A-SP-T-SP-T-SP-T-SP-M5C-SP-T-SP-A-SP-(2'-O-(2-METHOXYETHYL))M5RC-(2'-O-(2-METHOXYETHYL))R
Approvals — FDA: no, EMA: no, PMDA: no
Description: RG-101 2 mg/kg (n = 14)
Study: 28295463
Drug: RG-101 4
Normalized name: DNA, D((2'-O-(2-METHOXYETHYL))M5RC-SP-(2'-O-(2-METHOXYETHYL))RA-(2'-O-(2-METHOXYETHYL))RG-SP-(2'-O-(2-METHOXYETHYL))RG-(2'-O-(2-METHOXYETHYL))RA-SP-T-SP-A-SP-M5C-SP-A-SP-T-SP-T-SP-T-SP-M5C-SP-T-SP-A-SP-(2'-O-(2-METHOXYETHYL))M5RC-(2'-O-(2-METHOXYETHYL))R
Approvals — FDA: no, EMA: no, PMDA: no
Description: RG-101 4 mg/kg (n = 14)
Study: 23685845
Drug: Sildenafil treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil treatment in ED/DM group
Study: 26337285
Drug: Insulin initiation
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin initiation checklist
Study: 25220898
Drug: Pain that
Normalized name: Dermoplast Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pain that at least moderately interfered with daily living
Study: 8246275
Drug: Clomipramine 25
Normalized name: clomiPRAMINE 25 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomipramine 25 mg
Study: 7562355
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment (nonresorbable barrier)
Study: 2075848
Drug: Attending three
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Attending three weekly support meetings during the program
Study: 7033946
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 200 mg metoprolol and 2.5 mg indapamide
Study: 31980886
Drug: Intravenous lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous lidocaine infusion (1.5 mg/kg bolus followed by 1.5 mg/kg/h continuous infusion)
Study: 31796179
Drug: Afoxolaner (2.7-6.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Afoxolaner (2.7-6.9 mg/kg, PO)
Study: 31796179
Drug: Ivermectin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivermectin (300 μg/kg, SC)
Study: 31796179
Drug: Afoxolaner (monthly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Afoxolaner (monthly treatment for heavy infestations)
Study: 29090299
Drug: Palm oil
Normalized name: Palm Oil
DrugBank: Palm oil (DB14377)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palm oil (PO, 22.25 g)
Study: 29090299
Drug: Rice bran
Normalized name: Rice bran
DrugBank: Rice bran (DB14361)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rice bran oil (RBO, 22.25 g)
Study: 29090299
Drug: Palm oleogel
Normalized name: Palm Oil
DrugBank: Palm oil (DB14377)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palm oleogel (PG, 22.25 g oil + 2.75 g EC)
Study: 29090299
Drug: Rice bran
Normalized name: Rice bran
DrugBank: Rice bran (DB14361)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rice bran oleogel (RBG, 22.25 g oil + 2.75 g EC)
Study: 19394503
Drug: Nicardipine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine (0.5 microg/kg/min continuous infusion)
Study: 15232500
Drug: 5,000 U
Normalized name: Decara 25,000 UNT Vegicaps
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5,000 U of Botulinum toxin type B (BTX-B) treatment